Reported 1 day ago
Citizens JMP analyst Ivan Tuerkcan has initiated coverage of IDEAYA Biosciences (NASDAQ:IDYA) with a $41 price target, following the company's enrollment of the first patient in a Phase 1/2 clinical trial for non-small cell lung cancer. This trial, which tests a combination of IDE397 and Trodelvy, targets tumors with a specific genetic alteration present in about 20% of NSCLC patients. IDEAYA, focused on precision oncology, is conducting the trial in partnership with Gilead Sciences, who supplies Trodelvy.
Source: YAHOO